AI Article Synopsis
- Limited treatment options for glioblastoma (GBM) highlight the potential for targeting cancer-specific metabolic pathways by inhibiting key enzymes CPT1A and G6PD, which are vital for fatty acid oxidation and the pentose phosphate pathway.
- Experiments demonstrated that knocking down CPT1A and G6PD reduced GBM tumor cell viability and growth, supported by transcriptome analysis and metabolite profiling indicating disrupted metabolic pathways.
- The combination therapy using etomoxir and DHEA not only inhibited tumor growth in cell cultures but also extended survival in mice models, suggesting a promising therapeutic strategy for GBM.
Article Abstract
Purpose: Limited treatment options are currently available for glioblastoma (GBM), an extremely lethal type of brain cancer. For a variety of tumor types, bioenergetic deprivation through inhibition of cancer-specific metabolic pathways has proven to be an effective therapeutic strategy. Here, we evaluated the therapeutic effects and underlying mechanisms of dual inhibition of carnitine palmitoyltransferase 1A (CPT1A) and glucose-6-phosphate dehydrogenase (G6PD) critical for fatty acid oxidation (FAO) and the pentose phosphate pathway (PPP), respectively, against GBM tumorspheres (TSs).
Methods: Therapeutic efficacy against GBM TSs was determined by assessing cell viability, neurosphere formation, and 3D invasion. Liquid chromatography-mass spectrometry (LC-MS) and RNA sequencing were employed for metabolite and gene expression profiling, respectively. Anticancer efficacy in vivo was examined using an orthotopic xenograft model.
Results: CPT1A and G6PD were highly expressed in GBM tumor tissues. Notably, siRNA-mediated knockdown of both genes led to reduced viability, ATP levels, and expression of genes associated with stemness and invasiveness. Similar results were obtained upon combined treatment with etomoxir and dehydroepiandrosterone (DHEA). Transcriptome analyses further confirmed these results. Data from LC-MS analysis showed that this treatment regimen induced a considerable reduction in the levels of metabolites associated with the TCA cycle and PPP. Additionally, the combination of etomoxir and DHEA inhibited tumor growth and extended survival in orthotopic xenograft model mice.
Conclusion: Our collective findings support the utility of dual suppression of CPT1A and G6PD with selective inhibitors, etomoxir and DHEA, as an efficacious therapeutic approach for GBM.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11060-022-04189-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Met-Flow analyses of the metabolic heterogeneity associated with different stages of cord blood-derived hematopoietic cell differentiation.
Front Immunol
November 2024
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Article Synopsis
- The study investigates the metabolic activities of hematopoietic cells during different differentiation stages, focusing on human umbilical cord-derived cells like hematopoietic stem cells (HSCs) and various progenitor and differentiated blood cells.
- Findings reveal that HSCs have a high capacity for fatty acid synthesis, oxidation, and glucose uptake, showing enhanced metabolic functions compared to differentiated cell types.
- Specific metabolic pathways were highlighted, with distinct protein expressions observed in different progenitor cell populations, indicating a complex relationship between metabolism and hematopoietic differentiation.
TIM-3/Gal-9 interaction affects glucose and lipid metabolism in acute myeloid leukemia cell lines.
Front Immunol
December 2023
Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Introduction: T-cell immunoglobulin and mucin domain-3 (TIM-3) is a transmembrane molecule first identified as an immunoregulator. This molecule is also expressed on leukemic cells in acute myeloid leukemia and master cell survival and proliferation. In this study, we aimed to explore the effect of TIM-3 interaction with its ligand galectin-9 (Gal-9) on glucose and lipid metabolism in AML cell lines.
View Article and Find Full Text PDFElucidating the cell metabolic heterogeneity during hematopoietic lineage differentiation based on Met-Flow.
Int Immunopharmacol
August 2023
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600, China. Electronic address:
Cell metabolism is critically involved in the differentiation of the hematopoietic lineage and, therefore, has attracted the attention of researchers, however, in-depth studies on cellular metabolic activity of hematopoietic cells (HCs) require attention. This investigation compared the metabolic activity of HCs at critical lineage differentiation stages, including hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs), and differentiated blood cells, via multiple methods and basic reference values. Primary metabolic processes of HCs, including anabolism, catabolism, phosphate, and glucose metabolism, were analyzed, and their maps were drawn.
View Article and Find Full Text PDFPD-L1 stimulation can promote proliferation and survival of leukemic cells by influencing glucose and fatty acid metabolism in acute myeloid leukemia.
BMC Cancer
May 2023
Department of Immunology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: Leukemic cell metabolism plays significant roles in their proliferation and survival. These metabolic adaptations are under regulation by different factors. Programmed Death Ligand -1 (CD-274) is one of the immune checkpoint ligands that do not only cause the immune escape of cancer cells, but also have some intracellular effects in these cells.
View Article and Find Full Text PDFDual inhibition of CPT1A and G6PD suppresses glioblastoma tumorspheres.
J Neurooncol
December 2022
Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Article Synopsis
- Limited treatment options for glioblastoma (GBM) highlight the potential for targeting cancer-specific metabolic pathways by inhibiting key enzymes CPT1A and G6PD, which are vital for fatty acid oxidation and the pentose phosphate pathway.
- Experiments demonstrated that knocking down CPT1A and G6PD reduced GBM tumor cell viability and growth, supported by transcriptome analysis and metabolite profiling indicating disrupted metabolic pathways.
- The combination therapy using etomoxir and DHEA not only inhibited tumor growth in cell cultures but also extended survival in mice models, suggesting a promising therapeutic strategy for GBM.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!